surpass cvot tirzepatide results SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I Cardiovascular Outcomes with Tirzepatide versus
Pay in 4 interest-free payments of $7.45 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28












:max_bytes(150000):strip_icc()/VWH-GettyImages-1780222830-4ea0cf1f6f6e446aaa75a86f5b156df0.jpg)












